Pittenger & Anderson Inc Vertex Pharmaceuticals Inc Transaction History

Pittenger & Anderson Inc

$2.5 Billion
Q3 2024

A detailed history of Pittenger & Anderson Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Pittenger & Anderson Inc holds 939 shares of VRTX stock, worth $485,218. This represents 0.02% of its overall portfolio holdings.

Number of Shares

939

Previous 219 328.77%

Holding current value

$485,218

Previous $102,000 327.45%

% of portfolio

0.02%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$460.0 - $505.78 $331,200 - $364,161	720 Added 328.77%	939 $436,000
Q2 2024 Aug 09, 2024	BUY	$392.81 - $485.53 $86,025 - $106,331	219 New	219 $102,000
Q4 2022 Feb 10, 2023	BUY	$285.76 - $321.48 $92,872 - $104,481	325 New	325 $93,000
Q2 2021 Aug 13, 2021	SELL	$187.49 - $221.1 $17,436 - $20,562	-93 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$207.02 - $241.31 $109,720 - $127,894	-530 Reduced 85.07%	93 $20,000
Q4 2020 Feb 11, 2021	BUY	$207.01 - $276.09 $74,523 - $99,392	360 Added 136.88%	623 $147,000
Q3 2020 Nov 10, 2020	BUY	$255.65 - $303.1 $6,902 - $8,183	27 Added 11.44%	263 $72,000
Q1 2020 Apr 30, 2020	BUY	$199.77 - $247.81 $3,995 - $4,956	20 Added 9.26%	236 $56,000
Q4 2019 Feb 12, 2020	BUY	$166.71 - $223.91 $4,167 - $5,597	25 Added 13.09%	216 $47,000
Q1 2019 May 10, 2019	BUY	$163.73 - $194.7 $12,279 - $14,602	75 Added 64.66%	191 $35,000
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $607 - $768	4 Added 3.57%	116 $19,000
Q3 2018 Oct 12, 2018	BUY	$167.73 - $192.74 $1,174 - $1,349	7 Added 6.67%	112 $22,000
Q1 2018 May 08, 2018	BUY	$151.6 - $177.13 $15,918 - $18,598	105 New	105 $17,000

Others Institutions Holding VRTX

# of Institutions

1,717

Shares Held

226M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $133B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pittenger & Anderson Inc, based on Form 13F filings with the SEC.

News

Stay updated on Pittenger & Anderson Inc with notifications on news.

Account

Pittenger & Anderson Inc Vertex Pharmaceuticals Inc Transaction History